Epanova® for Lowering Very High Triglycerides

Phase 2/3 Completed 399 enrolled AstraZeneca

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Timeline

Start: 2011-01
Primary completion: 2012-03
Completion: 2012-04

Publications

Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014 Jan-Feb;8(1):94-106. doi: 10.1016/j.jacl.2013.10.003. Epub 2013 Oct 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	omefas	Unknown	2 g	—
Subject	omefas	Unknown	3 g	—
Subject	omefas	Unknown	4 g	—

Indications

No indication recorded.